Latest filings (excl ownership)
15-12G
Securities registration termination
24 Oct 22
8-K
Entry into a Material Definitive Agreement
21 Oct 22
8-K
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
19 Oct 22
8-K
Amendments to Articles of Incorporation or Bylaws
18 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Oct 22
POSASR
Automatic shelf registration (post-effective amendment)
13 Oct 22
25-NSE
Exchange delisting
13 Oct 22
25-NSE
Exchange delisting
13 Oct 22
425
Business combination disclosure
12 Oct 22
8-K
Entry into a Material Definitive Agreement
12 Oct 22
425
Business combination disclosure
7 Oct 22
8-K
Special Meeting of Securityholders
7 Oct 22
425
Business combination disclosure
4 Oct 22
8-K
Zymeworks Reminds Shareholders to Vote FOR its Redomicile
4 Oct 22
8-K
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
3 Oct 22
425
Business combination disclosure
26 Sep 22
8-K
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
26 Sep 22
425
Business combination disclosure
22 Sep 22
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
22 Sep 22
425
Business combination disclosure
16 Sep 22
8-K
Regulation FD Disclosure
16 Sep 22
8-K
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
12 Sep 22
425
Business combination disclosure
8 Sep 22
8-K
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
8 Sep 22
8-K
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
6 Sep 22
DEFM14A
Proxy related to merger
2 Sep 22
425
Business combination disclosure
2 Sep 22
8-K
Other Events
2 Sep 22
8-K
Unregistered Sales of Equity Securities
26 Aug 22
425
Business combination disclosure
19 Aug 22
8-K
Entry into a Material Definitive Agreement
19 Aug 22
8-K
Other Events
12 Aug 22
8-K
Material Change Report
5 Aug 22
8-K
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
4 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Zymeworks Announces Participation in Upcoming Investor Conferences
1 Aug 22
8-K
Regulation FD Disclosure
25 Jul 22
Latest ownership filings
SC 13G/A
BANK OF AMERICA CORP /DE/
14 Feb 23
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
6 Feb 23
4
Neil Josephson
14 Nov 22
SC 13G
Redmile Group, LLC
8 Aug 22
4
Paul Andrew Moore
19 Jul 22
3
Paul Andrew Moore
19 Jul 22
4
Neil Josephson
5 Jul 22
4
Neil A Klompas
5 Jul 22
SC 13D/A
All Blue Falcons FZE
26 May 22
SC 13D/A
All Blue Falcons FZE
20 May 22
SC 13D/A
All Blue Falcons FZE
28 Apr 22
SC 13D
All Blue Falcons FZE
22 Apr 22
4
Christopher Astle
11 Mar 22
4
Neil A Klompas
11 Mar 22
4
Neil Josephson
11 Mar 22
SC 13G/A
FMR LLC
10 Mar 22
3
Christopher Astle
4 Mar 22
SC 13G/A
PERCEPTIVE ADVISORS LLC
15 Feb 22
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 22
SC 13G
CREDIT SUISSE AG/
14 Feb 22
SC 13G
EVENTIDE ASSET MANAGEMENT, LLC
14 Feb 22
SC 13G/A
MORGAN STANLEY
11 Feb 22
SC 13G
GOLDMAN SACHS GROUP INC
11 Feb 22
SC 13G
MILLENNIUM MANAGEMENT LLC
10 Feb 22
SC 13G/A
FMR LLC
9 Feb 22
SC 13G
WELLINGTON MANAGEMENT GROUP LLP
4 Feb 22
SC 13G
BANK OF AMERICA CORP /DE/
31 Jan 22
4
Kenneth Galbraith
18 Jan 22
3
Kenneth Galbraith
18 Jan 22
4
Neil Josephson
11 Jan 22
4
Neil Josephson
7 Jan 22
4
Anthony J. Polverino
7 Jan 22
4
Neil A Klompas
7 Jan 22
4
Neil Josephson
12 Nov 21
4
Anthony J. Polverino
2 Sep 21
4
Ali Tehrani
16 Jul 21
4
Ali Tehrani
13 Jul 21
4
Kathryn O'Driscoll
8 Jul 21
4
Anthony J. Polverino
8 Jul 21
4
Neil A Klompas
8 Jul 21